Competitive ConcernsThe timing of the deal may suggest concerns about the quality of upcoming competitor data, motivating the execution of the deal ahead of the data announcement.
Macro IssuesMacro issues affecting biotech, such as pricing and tariffs, remain a concern for investors.
Safety RisksThere remains risk that larger BLU-808 trials will reveal a novel safety issue.